9305 Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers

Angiogenesis has been identified as a relevant target for melanoma experimental therapeutics, based on preclinical and clinical studies. A variety of angiogenesis inhibitors are currently being tested in both metastatic and adjuvant melanoma clinical trials. To date, the most promising evidence of benefit is based on a statistically nonsignificant trend in survival gain reported in a randomized phase II trial combining bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, with cytotoxic chemotherapy. Larger phase III studies are required to determine the true extent of clinical benefit with this class of agents. Key to these clinical trials is the need to include translational endpoints, since correlation of biological and clinical data will provide the opportunity to identify biomarkers predictive of treatment response. These biological studies will also aid our, as yet, poor understanding of the mechanism of action of angiogenesis inhibitors, as well as drug-related side effects. Finally, if these trials show meaningful clinical benefit, then careful consideration will need to be given when designing second-generation trials, in the light of novel gene-directed therapies currently showing promise in melanoma.

show abstract

9305 Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers

Cited by 2 publications

References 0 publications

Anti-Angiogenesis Therapy in Melanoma

Anti-Angiogenesis Therapy in Melanoma

Targeting angiogenesis in melanoma: prospects for the future

Contact Info

Product

Resources

About